Labtest has obtained registration approval for BioPorto Diagnostics' NGAL test reagent from the Brazilian health authorities. The approval covers the use of an NGAL assay for the diagnosis of acute kidney injury.
With the registration in Brazil, BioPorto has executed the first phase of its strategy for the BRIC (Brazil, Russia, India and China) markets, achieving regulatory approval to sell the NGAL test reagent in all the BRIC territories. BioPorto and its partners have already begun market penetration activities in these markets. The partnership with Labtest puts BioPorto in a favourable position to launch NGAL.